RecruitingNCT07491016
Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis
A Study on the Clinical Efficacy and Safety of Telitacicept Combined With Baricitinib in the Treatment of Difficult-to-Treat Rheumatoid Arthritis (D2T RA)
Sponsor
Zhejiang Provincial People's Hospital
Enrollment
30 participants
Start Date
Mar 1, 2026
Study Type
OBSERVATIONAL
Conditions
Summary
The aim of this study is to observe the clinical efficacy and safety of telitacicept combined with baricitinib in the treatment of D2TRA patients
Eligibility
Min Age: 18 YearsMax Age: 85 Years
Inclusion Criteria4
- \. Age 18-85 years
- \. Diagnosed with refractory rheumatoid arthritis according to the 2021 EULAR (European Alliance of Associations for Rheumatology) diagnostic criteria
- \. The traditional disease-improving rheumatic drug treatment is ineffective, and the use of two or more biological/targeted disease improving anti-rheumatic drugs is ineffective, and telitacicept combined with tofacitinib is required treated patients
- \. Voluntarily provided written informed consent
Exclusion Criteria8
- \. Exclusion of patients with severe diseases of major organs (e.g., heart, liver, or lungs)
- \. Patients with malignancies, hematological disorders, or other autoimmune diseases (excluding rheumatoid arthritis)
- \. History of allergy/hypersensitivity to the study medications (Telitacicept or Tofacitinib)
- \. Active tuberculosis or active infectious diseases requiring systemic treatment
- \. Pregnancy, lactation, or refusal to use contraception during the study
- \. Failure to complete the prescribed Telitacicept + Tofacitinib regimen due
- to:Non-adherence or Severe adverse reactions
- \. Other conditions contraindicating participation per investigator judgment
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07491016
Related Trials
A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
NCT0713759832 locations
A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)
NCT073635904 locations
Prospective Cohort Study on Refractory Rheumatoid Arthritis
NCT071264311 location
A Study of Intravenous CPTX2309 in Healthy Participants and Participants With Moderate to Severe Rheumatoid Arthritis (RA) or Systemic Lupus Erythematosus (SLE)
NCT069177421 location
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
NCT0381634552 locations